Not available
Quote | XBiotech Inc. (NASDAQ:XBIT)
Last: | $5.70 |
---|---|
Change Percent: | 0.0% |
Open: | $5.79 |
Close: | $5.70 |
High: | $5.875 |
Low: | $5.57 |
Volume: | 76,024 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | XBiotech Inc. (NASDAQ:XBIT)
AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) anti...
2024-06-06 21:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | XBiotech Inc. (NASDAQ:XBIT)
Subject | By | Source | When |
---|---|---|---|
XBiotech Commences Tender Offer to Purchase up to | Awl416 | investorshub | 05/17/2023 1:16:16 PM |
Have a look at this | europtiger | investorshub | 05/16/2023 11:40:41 PM |
should we be shorting? | Hokieman04 | investorshub | 05/16/2023 1:32:21 PM |
got some short data | amarinbullfromchicago | investorshub | 05/13/2023 3:57:00 PM |
where is the squeeze? | erostratus | investorshub | 05/13/2023 11:15:25 AM |
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) anti...
2024-06-06 21:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-16 07:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...